Atopic dermatitis (AD)

This clinical trial is testing an oral medication called TLL-018 in adults with moderate-to-severe atopic dermatitis, a chronic skin condition causing itchy, inflamed skin. The study aims to see if TLL-018 can significantly improve skin symptoms compared to a placebo. Participant…

This early-stage trial is testing an experimental drug called HXN6005 in healthy volunteers and in people with moderate-to-severe atopic dermatitis, a common form of eczema. The study is divided into three parts: first, healthy participants receive a single dose to check safety; …

This study tests whether upadacitinib, a drug already approved for eczema, can help people who have both atopic dermatitis (a type of eczema) with moderate to severe itching and a hard-to-treat autoimmune liver disease called cholangitis. The drug works by blocking a pathway invo…

This study looks at whether switching to a pill called ivarmacitinib can help people with moderate-to-severe eczema (atopic dermatitis) who did not get enough relief from standard injectable drugs. About 300 adults will take the pill for 16 weeks. The goal is to see if their skin…

This phase 3 trial compares a new injectable drug, GS101, to the established treatment Dupixent for adults with moderate-to-severe atopic dermatitis (eczema). About 572 participants will receive either GS101 or Dupixent every other week for a year. The main goal is to see if GS10…

This study will test the drug ivarmacitinib in 1,000 people aged 12 to 75 with moderate-to-severe atopic dermatitis (eczema). Participants take a daily pill for up to 52 weeks, with the option to adjust the dose. Researchers will measure how well the drug clears skin rashes and r…

This Phase 3 trial tests a medicated foam called OPA-15406 (difamilast) for atopic dermatitis (eczema) in children aged 2 and older, and infants under 2. About 198 participants will apply the foam twice daily for 8 weeks. The main goal is to see if the foam clears or nearly clear…

This study tests a new injectable drug called SIM0278 for adults with moderate to severe atopic dermatitis (eczema) that needs systemic treatment. About 184 participants will receive either a low, medium, or high dose of SIM0278 or a placebo. The main goal is to see how much ecze…

This Phase 3 trial tests a medicated foam called OPA-15406 (difamilast) for adults with atopic dermatitis, a common skin condition causing red, itchy rashes. About 156 participants will apply the foam or a placebo twice daily for 4 weeks. The goal is to see if the foam clears or …

This study tests whether crisaborole 2% ointment works better than tacrolimus 0.1% ointment for children aged 2-18 with mild to moderate eczema. 66 children will apply one of the creams twice daily for 28 days. The main goal is to see how many achieve clear or almost clear skin b…

Researchers are testing an experimental biologic drug called PRA-216 in adults with moderate to severe atopic dermatitis, a form of eczema. The trial compares PRA-216 with a placebo to see whether the drug is safe and can reduce eczema severity. Participants must have had eczema …

This study tests whether a medicated cream called crisaborole works better than a placebo cream for people with mild to moderate eczema. About 270 people aged 12 to 50 will apply the cream twice daily for four weeks. The goal is to see if the cream can clear or nearly clear the e…

This study looks at whether applying moisturizer while still in the shower or bath is better than applying it after towel drying for teens with eczema. Thirty participants aged 12-18 will try each method for one month and report which they prefer. Researchers will also measure sk…

Researchers are studying where the bacteria that infect skin sores come from in people with scabies or atopic dermatitis. They will compare bacteria grown from infected skin lesions with bacteria from nasal swabs to see if the same species appear in both places. A group of health…

This study will follow 50 Costa Rican patients with moderate-to-severe atopic dermatitis (eczema) who are receiving advanced treatments like dupilumab or JAK inhibitors as part of their regular care. Researchers will collect information on patient characteristics, treatment patte…